CD274 and cancer: In addition, no abnormal weight or temperature changes of mice were observed in the HMME/R837@Lip-SDT plus anti-PD-L1 group (Fig. 5j, k), indicating the high therapeutic biosafety of the combined cancer SDT and immunotherapy.